CTOs on the Move

Aspen Neuroscience

www.aspenneuroscience.com

 
Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kim Raineri
Chief Technology Officer Profile

Funding

Aspen Neuroscience raised $70M on 04/01/2020
Aspen Neuroscience raised $147.5M on 05/09/2022

Similar Companies

Agenta Biotechnologies

Agenta Biotechnologies is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genomenon

Genomenon is an AI-driven genomics company whose mission is to save and improve lives by making genomic information actionable for patients with rare genetic diseases and cancer.

Q-Chuck Technologies

Q-Chuck Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

Aerpio Therapeutics

Aerpio Therapeutics is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector. Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.